<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Psychopharmacol</journal-id><journal-id journal-id-type="publisher-id">JOP</journal-id><journal-id journal-id-type="hwp">spjop</journal-id><journal-title-group><journal-title>Journal of Psychopharmacology (Oxford, England)</journal-title></journal-title-group><issn pub-type="ppub">0269-8811</issn><issn pub-type="epub">1461-7285</issn><publisher><publisher-name>Sage Publications</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">19423614</article-id><article-id pub-id-type="pmc">2841520</article-id><article-id pub-id-type="doi">10.1177/0269881109105679</article-id><article-id pub-id-type="publisher-id">10.1177_0269881109105679</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Papers</subject></subj-group></article-categories><title-group><article-title>Lack of effect of citalopram on magnetic resonance spectroscopy
                    measures of glutamate and glutamine in frontal cortex of healthy
                volunteers</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Taylor</surname><given-names>MJ</given-names></name><aff>Department of Psychiatry, University of Oxford, Warneford Hospital, Oxford,
                        United Kingdom</aff><xref ref-type="corresp" rid="corresp1-0269881109105679"/></contrib><contrib contrib-type="author"><name><surname>Norbury</surname><given-names>R</given-names></name><aff>Department of Psychiatry, University of Oxford, Warneford Hospital, Oxford,
                        United Kingdom</aff></contrib><contrib contrib-type="author"><name><surname>Murphy</surname><given-names>S</given-names></name><aff>Department of Psychiatry, University of Oxford, Warneford Hospital, Oxford,
                        United Kingdom</aff></contrib><contrib contrib-type="author"><name><surname>Rudebeck</surname><given-names>S</given-names></name><aff>Department of Psychiatry, University of Oxford, Warneford Hospital, Oxford,
                        United Kingdom</aff></contrib><contrib contrib-type="author"><name><surname>Jezzard</surname><given-names>P</given-names></name><aff>The Centre for Functional Magnetic Resonance Imaging of the Brain,
                        University of Oxford, John Radcliffe Hospital, Oxford, United Kingdom</aff></contrib><contrib contrib-type="author"><name><surname>Cowen</surname><given-names>PJ</given-names></name><aff>Department of Psychiatry, University of Oxford, Warneford Hospital, Oxford,
                        United Kingdom</aff></contrib></contrib-group><author-notes><corresp id="corresp1-0269881109105679">Dr Matthew Taylor, University Department of
                    Psychiatry, Warneford Hospital, Oxford OX3 7JX, United Kingdom. Email:
                        <email>matthew.taylor@psych.ox.ac.uk</email></corresp></author-notes><pub-date pub-type="epub-ppub"><month>8</month><year>2010</year></pub-date><!--Fake  ppub date generated  by PMC from publisher pub-date/@pub-type='epub-ppub' --><pub-date pub-type="ppub"><month>8</month><year>2010</year></pub-date><volume>24</volume><issue>8</issue><fpage>1217</fpage><lpage>1221</lpage><permissions><copyright-statement>&#x000a9; The Author(s) 2010. Published by SAGE. All rights
                    reserved. SAGE Publications</copyright-statement><copyright-year>2010</copyright-year><copyright-holder content-type="society">British Association for Psychopharmacology</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0/"><license-p>This is an open-access article distributed under the terms of the Creative
                        Commons Attribution License, which permits unrestricted use, distribution,
                        and reproduction in any medium, provided the original work is properly
                        cited.</license-p></license></permissions><abstract><p>Magnetic resonance spectroscopy (MRS) is a non-invasive imaging technique that
                    can provide localised measures of brain chemistry <italic>in vivo</italic>. We
                    previously found that healthy volunteers receiving the selective serotonin
                    reuptake inhibitor, citalopram, daily for 1 week showed higher levels of a
                    combined measure of glutamate and glutamine (Glx) in occipital cortex than those
                    receiving placebo. The aim of this study was to assess if a similar effect could
                    be detected in the frontal brain region. Twenty-three healthy volunteers
                    randomised to receive either citalopram 20 mg or a placebo capsule daily for
                    7&#x02013;10 days were studied and scanned using a 3T Varian INOVA system
                    before and at the end of treatment. Standard short-TE (echo time) PRESS
                    (Point-resolved spectroscopy) (TE = 26 ms) and PRESS-J spectra were acquired
                    from a single 8-cm<sup>3</sup> voxel in a frontal region incorporating anterior
                    cingulate cortex. Glutamate and total Glx levels were quantified both relative
                    to creatine and as absolute levels. Relative to placebo, citalopram produced no
                    change in Glx or glutamate alone at the end of the study. Similarly, no effect
                    was seen on other MRS measures studied: myo-inositol, choline,
                    <italic>N</italic>-acetylaspartate and creatine. These data suggest that the
                    effects of serotonin reuptake to modify cortical glutamatergic MRS measures may
                    be regionally specific. This supports the potential for MRS in assessing
                    neuroanatomically specific serotonin-glutamate interactions in the human
                brain.</p></abstract><kwd-group><kwd>citalopram</kwd><kwd>frontal cortex</kwd><kwd>glutamate</kwd><kwd>magnetic resonance spectroscopy</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="sec1-0269881109105679"><title>Introduction</title><p>Proton magnetic resonance spectroscopy (MRS) is an imaging technique providing safe
                and non-invasive measurements of aspects of brain chemistry. A range of measures can
                be obtained including glutamate and the related compound, glutamine. At the field
                strengths generally available for use in human studies (up to 3 Tesla), reliably
                separating the MRS signals from glutamate and glutamine is challenging, so the
                combined level of both glutamate and glutamine (Glx) is often reported (<xref ref-type="bibr" rid="bibr20-0269881109105679">Malhi, <italic>et al</italic>.,
                    2002</xref>).</p><p>One of the most consistent findings in MRS studies of acute major depressive disorder
                is lower Glx levels in frontal brain regions (<xref ref-type="bibr" rid="bibr1-0269881109105679">Auer, <italic>et al</italic>., 2000</xref>; <xref ref-type="bibr" rid="bibr13-0269881109105679">Hasler, <italic>et al</italic>.,
                    2007</xref>; <xref ref-type="bibr" rid="bibr31-0269881109105679">Yildiz-Yesiloglu and Ankerst, 2006</xref>). Glutamate released into the
                extracellular space during neurotransmission is rapidly taken up by astrocytes and
                converted to glutamine which can be safely transported back to neurons (<xref ref-type="bibr" rid="bibr8-0269881109105679">Danbolt, 2001</xref>). This
                glutamate-glutamine cycle is a major component of brain energetics (<xref ref-type="bibr" rid="bibr16-0269881109105679">Hyder, <italic>et al</italic>.,
                    2006</xref>). The reduced levels of Glx suggest some abnormality of this
                glutamate-glutamine cycle is present during the depressive episodes. Interestingly,
                it appears that Glx levels in this region return to normal with full clinical
                recovery (<xref ref-type="bibr" rid="bibr4-0269881109105679">Bhagwagar, <italic>et
                        al</italic>., 2008</xref>; <xref ref-type="bibr" rid="bibr12-0269881109105679">Hasler, <italic>et al</italic>., 2005</xref>).</p><p>Serotonergic agents used in the treatment of depression, such as the selective
                serotonin reuptake inhibitors (SSRIs), are well placed to modify this
                glutamate-glutamine cycle, either by actions on neuronal populations to modify the
                glutamate release or by modulating the astrocyte activity. Serotonergic projections
                extend throughout cortex (<xref ref-type="bibr" rid="bibr14-0269881109105679">Hornung, 2003</xref>), and serotonin receptors are found on both neuronal and
                astrocyte populations (<xref ref-type="bibr" rid="bibr9-0269881109105679">Eastwood,
                        <italic>et al</italic>., 2001</xref>; <xref ref-type="bibr" rid="bibr17-0269881109105679">Jakab and Goldman-Rakic, 1998</xref>, 2000).</p><p>Recently, we reported that 1 week of citalopram administration at a standard clinical
                dose was associated with an increase in Glx levels in a posterior cortical region in
                healthy volunteers (<xref ref-type="bibr" rid="bibr28-0269881109105679">Taylor,
                        <italic>et al</italic>., 2008</xref>). The aim of this study was to assess
                whether a similar finding could be detected in the frontal cortex. In addition, we
                also used an additional MRS technique, PRESS-J, which permits the measurement of
                glutamate without glutamine at moderate field strengths (<xref ref-type="bibr" rid="bibr15-0269881109105679">Hurd, <italic>et al</italic>., 2004</xref>).</p></sec><sec sec-type="materials|methods" id="sec2-0269881109105679"><title>Materials and methods</title><sec id="sec3-0269881109105679"><title>Design</title><p>We studied 23 healthy volunteers (11 male, 12 female; mean age 23 years, range
                    19&#x02013;32) who were free of any axis I diagnosis assessed using the
                    Standardised Clinical Interview for Diagnostic and Statistical Manual of Mental
                    Disorders-IV (First, <italic>et al</italic>., 1997) and had received no
                    psychoactive medications for at least 3 months before commencing the study. They
                    were also free of any physical illness and taking no medications except the oral
                    contraceptive pill. Participants were randomly assigned to receive either
                    citalopram 20 mg or placebo daily for 7&#x02013;10 days (the variable time
                    of treatment was necessary to allow for scanner availability). Magnetic
                    resonance imaging (MRI) was performed in the afternoon before starting
                    medication (day 0) and on the day of the final capsule (typically day 7, but day
                    10 for three participants). Baseline and endpoint mental states and personality
                    traits were assessed by questionnaires (Beck Depression Inventory, Spielberger
                    State Anxiety Inventory and the Positive and Negative Affect Scale).</p><p>Spectroscopy data were acquired using a 3T Varian INOVA system with a head
                    optimised gradient coil (Tesla Engineering, Storrington, West Sussex, UK) and a
                    head-only transmit/receive quadrature birdcage radiofrequency coil. Data were
                    acquired from a 20 &#x000d7; 20 &#x000d7; 20 mm voxel placed in medial
                    prefrontal cortex anterior to the genu of the corpus callosum (<xref ref-type="fig" rid="fig1-0269881109105679">Figure 1</xref>). The voxel was
                    positioned manually by reference to an axial
                    <italic>T</italic><sub>1</sub>-weighted gradient-echo image. PRESS data (<xref ref-type="bibr" rid="bibr6-0269881109105679">Bottomley, 1987</xref>) with
                    (TE 26 ms, TR 3 s, averages = 64) and without (TE 26 ms, TR 3 s, averages = 1)
                    water suppressions were acquired. PRESS-J data (<xref ref-type="bibr" rid="bibr15-0269881109105679">Hurd, <italic>et al</italic>., 2004</xref>)
                    with and without water suppressions were similarly acquired with TE arrayed from
                    35 to 195 ms in 10 ms increments (water-suppressed data, total acquisitions =
                    128; non-water suppressed data, total acquisitions = 16; TR = 3 s).
                        <italic>T</italic><sub>1</sub>-weighted structural images of whole brain
                    were acquired (2 mm<sup>3</sup> voxel size). A higher resolution structural
                    image was acquired on a separate occasion using a 1.5 T Siemens Sonata (Siemens,
                    Camberley, UK) scanner using a Turbo FLASH sequence (TR 12 ms, TE 5.65 ms, voxel
                    size = 1 mm<sup>3</sup>). <fig id="fig1-0269881109105679" position="float"><label>Figure 1</label><caption><p>(A) Frontal voxel positioned to include pregenual cingulate cortex
                                (Brodmann areas 24 and 32). (B) Sample PRESS spectrum (echo time 26
                                ms). (C) Sample PRESS-J spectrum. The PRESS-J spectrum resembles
                                standard PRESS with similar peaks for N-acetylaspartate (NAA),
                                choline (Cho), myo-inositol (mI) and creatine (Cr). However, the Glx
                                doublet is replaced by a singlet glutamate (Glu) peak at 2.35
                            ppm.</p></caption><graphic xlink:href="10.1177_0269881109105679-fig1"/></fig></p></sec><sec id="sec4-0269881109105679"><title>MRS analyses</title><p>PRESS data were analysed with LCModel (Stephen Provencher Inc., Oakville,
                    Ontario, Canada) (<xref ref-type="bibr" rid="bibr24-0269881109105679">Provencher, 1993</xref>), using the non-water suppressed data for eddy
                    current correction, calculating the metabolite concentrations relative to
                    creatine in conventional fashion using 15 metabolite basis spectra and simulated
                    lipid and macromolecule components. PRESS-J data were pre-processed by
                    zero-order phase correction, apodisation with a 5 Hz Gaussian filter and summing
                    of the 16 constituent spectra before analysis. Analysis of the PRESS-J data used
                    Advanced Method for Accurate, Robust, and Efficient Spectral fitting (AMARES)
                        (<xref ref-type="bibr" rid="bibr30-0269881109105679">Vanhamme, <italic>et
                        al</italic>., 1997</xref>) since metabolite basis spectra were not available
                    for PRESS-J acquisitions, and the spectral simplification and flat baselines
                    obtained with this technique <italic>in vivo</italic> make direct single peak
                    fitting reliable (<xref ref-type="bibr" rid="bibr15-0269881109105679">Hurd,
                            <italic>et al</italic>., 2004</xref>).</p></sec><sec id="sec5-0269881109105679"><title>Voxel composition</title><p>FMRIB Software Library (University of Oxford, Oxford, UK) FMRIB Automated
                    Segmentation Tool (<xref ref-type="bibr" rid="bibr32-0269881109105679">Zhang,
                            <italic>et al</italic>., 2001</xref>) was used to segment the
                    high-resolution structural brain images into grey matter, white matter and
                    cerebrospinal fluid (CSF), to allow estimation of voxel composition.</p></sec><sec id="sec6-0269881109105679"><title>Absolute quantitation</title><p>The spectroscopy analyses using LCModel and AMARES yielded estimates of
                    concentration relative to creatine. A level referenced to tissue water was also
                    obtained for each measure by correcting for voxel creatine levels (<xref ref-type="bibr" rid="bibr2-0269881109105679">Barker, <italic>et
                        al</italic>., 1993</xref>). PRESS-J data were used to estimate both creatine
                    and water levels at <italic>t</italic> = 0, that is, without effects of
                        <italic>T</italic><sub>2</sub> decay. Since simply referencing to internal
                    tissue water has been found to underestimate concentrations (<xref ref-type="bibr" rid="bibr7-0269881109105679">Brooks, <italic>et
                        al</italic>., 1999</xref>), the values referenced to tissue water were
                    corrected for voxel CSF content and for differences in fractional grey and white
                    matter water density (Lentner, 1981) to provide an estimate of absolute levels.
                    In the absence of an external reference water standard, these are reported in
                    arbitrary units.</p></sec><sec id="sec7-0269881109105679"><title>Statistical analyses</title><p>Results were analysed using the general linear model with time (pre- and
                    post-treatments) as the within subjects factor and group (placebo vs citalopram)
                    as between subjects factor. For technical reasons, full data sets were not
                    available for four participants. Sensitivity analyses were performed for the
                    effect of including additional factors (gender) and covariates (age, difference
                    in grey matter, white matter and CSF) in the model. Correlations were calculated
                    as Pearson&#x02019;s product-moment correlation coefficient
                        (<italic>r</italic><sup>2</sup>). Repeatability coefficients and
                    coefficients of variation for data from the placebo group were calculated.
                    Statistical analyses were performed in R (R Foundation for Statistical
                    Computing, Vienna, Austria) (version 2.5) and SPSS (SPSS Inc., Chicago, IL, USA)
                    (version 15).</p></sec></sec><sec sec-type="results" id="sec8-0269881109105679"><title>Results</title><sec id="sec9-0269881109105679"><title>Participants</title><p>Of the 23 participants, 13 received citalopram and 10 received placebo. The
                    groups did not differ in baseline scores of anxiety and depression, days of
                    treatment, or post-treatment mood or anxiety (<xref ref-type="table" rid="table1-0269881109105679">Table 1</xref>). <table-wrap id="table1-0269881109105679" position="float"><label>Table 1</label><caption><p>Group characteristics</p></caption><table frame="hsides" rules="groups"><thead align="left"><tr><th rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">Citalopram (<italic>n</italic> = 13)</th><th align="left" rowspan="1" colspan="1">Placebo (<italic>n</italic> = 10)</th></tr></thead><tbody align="left"><tr><td rowspan="1" colspan="1">Age</td><td rowspan="1" colspan="1">23 (3)</td><td rowspan="1" colspan="1">24 (3)</td></tr><tr><td rowspan="1" colspan="1">Gender</td><td align="left" rowspan="1" colspan="1">5 female, 8 male</td><td align="left" rowspan="1" colspan="1">7 female, 3 male</td></tr><tr><td colspan="3" rowspan="1">Beck Depression Inventory</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Start</td><td rowspan="1" colspan="1">1.5 (1.7)</td><td rowspan="1" colspan="1">1.8 (2.3)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Endpoint</td><td rowspan="1" colspan="1">1.5 (2.1)</td><td rowspan="1" colspan="1">1.4 (2.1)</td></tr><tr><td colspan="3" rowspan="1">Positive and Negative Affect Scale
                                    (positive)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Start</td><td rowspan="1" colspan="1">35.7 (6.9)</td><td rowspan="1" colspan="1">37.5 (6.9)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Endpoint</td><td rowspan="1" colspan="1">31.0 (7.2)</td><td rowspan="1" colspan="1">36.8 (6.8)</td></tr><tr><td colspan="3" rowspan="1">Positive and Negative Affect Scale
                                    (negative)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Start</td><td rowspan="1" colspan="1">13.7 (6.7)</td><td rowspan="1" colspan="1">11.1 (1.6)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Endpoint</td><td rowspan="1" colspan="1">13.1 (4.8)</td><td rowspan="1" colspan="1">10.2 (0.4)</td></tr><tr><td colspan="3" rowspan="1">Spielberger State Anxiety Inventory</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Start</td><td rowspan="1" colspan="1">32 (10.9)</td><td rowspan="1" colspan="1">28 (8.2)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Endpoint</td><td rowspan="1" colspan="1">33 (11.0)</td><td rowspan="1" colspan="1">26 (6.5)</td></tr></tbody></table><table-wrap-foot><fn id="table-fn1-0269881109105679"><p>Means with standard deviations. No significant differences
                                    between groups.</p></fn></table-wrap-foot></table-wrap></p></sec><sec id="sec10-0269881109105679"><title>Voxel characteristics</title><p>The spectroscopy data acquired were from a medial prefrontal voxel incorporating
                    pregenual cingulate cortex (Brodmann areas 24 and 32; <xref ref-type="fig" rid="fig1-0269881109105679">Figure 1</xref>). The voxel composition did not
                    differ between groups or between sessions, and on average, it contained 73% grey
                    matter, 15% white matter and 12% CSF.</p></sec><sec id="sec11-0269881109105679"><title>MRS results</title><p>There was no significant effect of treatment on any of the MRS measures studied.
                    No main effect of group or time, or group &#x000d7; time interactions were
                    found on analyses of Glx, glutamate, myo-inositol, choline,
                    <italic>N</italic>-acetylaspartate or creatine whether concentrations were
                    expressed relative to creatine or as absolute concentrations (<xref ref-type="fig" rid="fig2-0269881109105679">Figure 2</xref>). <fig id="fig2-0269881109105679" position="float"><label>Figure 2</label><caption><p>Levels of glutamate + glutamine (Glx) and glutamate, in anterior
                                cingulate cortex before and after 1 week&#x02019;s administration
                                of citalopram 20 mg daily (<italic>n</italic> = 13, open circles) or
                                placebo (<italic>n</italic> = 10, closed circles) in healthy
                                volunteers. (A) Levels relative to creatine (Cr). (B) Absolute
                                levels in arbitrary units, individual measures (points joined by
                                dotted lines) and group means (dashed lines). No significant group
                                &#x000d7; time interactions observed (Glx/Cr F(1,19) = 0.558,
                                    <italic>P</italic> = 0.464; Glu/Cr F(1,19) = 0.063,
                                <italic>P</italic> = 0.805; Glx F(1,17) = 0.002, <italic>P</italic>
                                = 0.964; Glu F(1,17) = 1.122, <italic>P</italic> = 0.304).</p></caption><graphic xlink:href="10.1177_0269881109105679-fig2"/></fig></p><p>Measures of Glx and glutamate showed good repeatability across sessions, with
                    mean coefficients of variation of 5.3 and 6.8% for levels relative to creatine
                    and 6.8 and 7.4% referenced to tissue water, with repeatability coefficients
                    from 0.18 to 0.25. Some correlation between Glx and glutamate measures was
                    observed (<italic>r</italic><sup>2</sup> = 0.22 with creatine referencing and
                        <italic>r</italic><sup>2</sup> = 0.25 with water referencing,
                    <italic>P</italic> &#x0003c; 0.05 in both cases).</p></sec><sec id="sec12-0269881109105679"><title>Effect of composition on metabolite levels</title><p>For estimates of concentrations relative to creatine, voxel white matter content
                    was correlated with myo-inositol (<italic>r</italic><sup>2</sup> = 0.33,
                        <italic>P</italic> &#x0003c; 0.05) and inversely correlated with Glx
                        (<italic>r</italic><sup>2</sup> = 0.31, <italic>P</italic> &#x0003c; 0.05).
                    For absolute concentration estimates, the inverse correlation of Glx with white
                    matter content remained (<italic>r</italic><sup>2</sup> = 0.4,
                    <italic>P</italic> &#x0003c; 0.05).</p></sec></sec><sec sec-type="discussion" id="sec13-0269881109105679"><title>Discussion</title><p>The main finding of this study was an absence of effect of 1 week&#x02019;s
                citalopram on MRS measures of glutamate and Glx in anterior cingulate cortex in
                healthy volunteers. This was the case whether concentrations were expressed relative
                to creatine or as absolute levels.</p><p>This lack of effect seems unlikely to be simply explained by the short duration of
                anti-depressant administration. Although courses of anti-depressant treatment
                typically last for extended periods, clinical trial data indicate that the
                beneficial effects of SSRIs relative to placebo in the treatment of depression can
                be detected after only 1 week (<xref ref-type="bibr" rid="bibr29-0269881109105679">Taylor, <italic>et al</italic>., 2006</xref>). Also in healthy volunteers, 1
                week of citalopram is associated with consistent changes in emotional processing
                without overt changes in mood (<xref ref-type="bibr" rid="bibr11-0269881109105679">Harmer, <italic>et al</italic>., 2004</xref>), and functional MRI reveals
                associated changes in neural activity in regions including prefrontal cortex (<xref ref-type="bibr" rid="bibr10-0269881109105679">Harmer, <italic>et al</italic>.,
                    2006</xref>). Furthermore, our previous data suggest that the intervention used
                here increases Glx in occipito-parietal cortex in healthy volunteers (<xref ref-type="bibr" rid="bibr28-0269881109105679">Taylor, <italic>et al</italic>.,
                    2008</xref>).</p><p>The use of the PRESS-J technique enabled us to measure both glutamate and Glx in this
                study, but no effect of citalopram on either measure was seen. Glutamine levels were
                not measured directly, but in the absence of changes in glutamate, altered glutamine
                would be reflected in changed Glx levels. Therefore, these data suggest that there
                was no reliable change in glutamine levels. Glx estimates sometimes contain a
                component attributable to &#x003b3;-aminobutryic acid (GABA) (<xref ref-type="bibr" rid="bibr26-0269881109105679">Sanacora, <italic>et al</italic>.,
                    2008</xref>), and SSRI treatments in healthy subjects can alter GABA levels.
                However, the magnitude of changes in GABA that might be expected (<xref ref-type="bibr" rid="bibr5-0269881109105679">Bhagwagar, <italic>et al</italic>.,
                    2004</xref>; <xref ref-type="bibr" rid="bibr28-0269881109105679">Taylor,
                        <italic>et al</italic>., 2008</xref>) would only change Glx estimates by a
                few percent, which this study lacks the power to detect. Studies using specific
                sequences to measure GABA would be required to clarify this point (<xref ref-type="bibr" rid="bibr21-0269881109105679">Mescher, <italic>et al</italic>.,
                    1998</xref>).</p><p>The regional differences, in effect of citalopram, with increased Glx evident in
                occipital region (<xref ref-type="bibr" rid="bibr28-0269881109105679">Taylor,
                        <italic>et al</italic>., 2008</xref>) but not in the anterior cingulate in
                this study complement a regional pattern of glutamatergic abnormalities in
                depression and after recovery. Although acute depression is associated with lowered
                Glx in anterior cingulate cortex (<xref ref-type="bibr" rid="bibr1-0269881109105679">Auer, <italic>et al</italic>., 2000</xref>; <xref ref-type="bibr" rid="bibr13-0269881109105679">Hasler, <italic>et al</italic>., 2007</xref>;
                    <xref ref-type="bibr" rid="bibr23-0269881109105679">Pfleiderer, <italic>et
                    al</italic>., 2003</xref>) and dorsolateral prefrontal cortex (<xref ref-type="bibr" rid="bibr22-0269881109105679">Michael, <italic>et al</italic>.,
                    2003</xref>), increased glutamate is reported in occipital cortex (<xref ref-type="bibr" rid="bibr25-0269881109105679">Sanacora, <italic>et al</italic>.,
                    2004</xref>). After recovery, increased Glx is found in occipital cortex (<xref ref-type="bibr" rid="bibr3-0269881109105679">Bhagwagar, <italic>et al</italic>.,
                    2007</xref>), whereas levels are normalised in anterior cingulate (<xref ref-type="bibr" rid="bibr4-0269881109105679">Bhagwagar, <italic>et al</italic>.,
                    2008</xref>; <xref ref-type="bibr" rid="bibr12-0269881109105679">Hasler,
                        <italic>et al</italic>., 2005</xref>). Taken together, it is possible that
                MRS identifies region-specific effects of serotonin reuptake inhibitors on
                glutamatergic function. The functional significance of this pattern of
                serotonin-glutamate interactions effects remains to be elucidated.</p><p>Finally, it is worth noting that although no change in levels of MRS Glx or glutamate
                were detected following citalopram treatment in this study, it is certainly possible
                that citalopram might induce more subtle changes in glutamate-glutamine cycling
                which would not be detected by the present methodology. For example, proton MRS does
                not provide a specific measure of synaptic glutamate levels and changes in glutamate
                release within neurotransmission might be masked by compensatory changes elsewhere.
                As noted in the Introduction section, the process of glutamate-glutamine cycling is
                very important in regulating brain neuronal activity and conceivably might be a
                target for psychotropic drug treatment. However, to study such effects, it will be
                necessary to use advanced MRS techniques, such as carbon-13 MRS (<xref ref-type="bibr" rid="bibr27-0269881109105679">Shen, <italic>et al</italic>.,
                    1999</xref>).</p></sec></body><back><ack><title>Acknowledgements</title><p>This study was funded by the Wellcome Trust. MJT was a Wellcome Trust Research
                Training Fellow. SM was supported by a Wellcome Trust studentship. PJC is a MRC
                Clinician Scientist. We thank Dr John Evans for his assistance in protocol
                development.</p></ack><sec id="sec14-0269881109105679"><title>Declaration of conflicts of interest</title><p>Professor Cowen has been a paid member of advisory boards of Eli Lilly, Servier and
                Wyeth and has been a paid lecturer for Eli Lilly, Servier and Glaxo Smith Kline.</p></sec><ref-list><title>References</title><ref id="bibr1-0269881109105679"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Auer</surname><given-names>DP</given-names></name><name><surname>Putz</surname><given-names>B</given-names></name><name><surname>Kraft</surname><given-names>E</given-names></name><name><surname>Lipinski</surname><given-names>B</given-names></name><name><surname>Schill</surname><given-names>J</given-names></name><name><surname>Holsboer</surname><given-names>F</given-names></name></person-group> (<year>2000</year>) <article-title>Reduced glutamate in the
                        anterior cingulate cortex in depression: an in vivo proton magnetic
                        resonance spectroscopy study</article-title>. <source>Biol Psychiatry</source><volume>47</volume>:
                <fpage>305</fpage>&#x02013;<lpage>313</lpage><pub-id pub-id-type="pmid">10686265</pub-id></mixed-citation></ref><ref id="bibr2-0269881109105679"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barker</surname><given-names>PB</given-names></name><name><surname>Soher</surname><given-names>BJ</given-names></name><name><surname>Blackband</surname><given-names>SJ</given-names></name><name><surname>Chatham</surname><given-names>JC</given-names></name><name><surname>Mathews</surname><given-names>VP</given-names></name><name><surname>Bryan</surname><given-names>RN</given-names></name></person-group> (<year>1993</year>) <article-title>Quantitation of proton NMR
                        spectra of the human brain using tissue water as an internal concentration
                        reference</article-title>. <source>NMR Biomed</source><volume>6</volume>: <fpage>89</fpage>&#x02013;<lpage>94</lpage><pub-id pub-id-type="pmid">8384470</pub-id></mixed-citation></ref><ref id="bibr3-0269881109105679"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bhagwagar</surname><given-names>Z</given-names></name><name><surname>Wylezinska</surname><given-names>M</given-names></name><name><surname>Jezzard</surname><given-names>P</given-names></name><name><surname>Evans</surname><given-names>J</given-names></name><name><surname>Ashworth</surname><given-names>F</given-names></name><name><surname>Sule</surname><given-names>A</given-names></name><etal/></person-group> (<year>2007</year>) <article-title>Reduction in occipital cortex
                        gamma-aminobutyric acid concentrations in medication-free recovered unipolar
                        depressed and bipolar subjects</article-title>. <source>Biol Psychiatry</source><volume>61</volume>:
                <fpage>806</fpage>&#x02013;<lpage>812</lpage><pub-id pub-id-type="pmid">17210135</pub-id></mixed-citation></ref><ref id="bibr4-0269881109105679"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bhagwagar</surname><given-names>Z</given-names></name><name><surname>Wylezinska</surname><given-names>M</given-names></name><name><surname>Jezzard</surname><given-names>P</given-names></name><name><surname>Evans</surname><given-names>J</given-names></name><name><surname>Boorman</surname><given-names>E</given-names></name><name><surname>Matthews</surname><given-names>PM</given-names></name><etal/></person-group> (<year>2008</year>) <article-title>Low GABA concentrations in
                        occipital cortex and anterior cingulate cortex in medication-free, recovered
                        depressed patients</article-title>. <source>Int J Neuropsychopharmacol</source><volume>11</volume>:
                <fpage>255</fpage>&#x02013;<lpage>260</lpage><pub-id pub-id-type="pmid">17625025</pub-id></mixed-citation></ref><ref id="bibr5-0269881109105679"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bhagwagar</surname><given-names>Z</given-names></name><name><surname>Wylezinska</surname><given-names>M</given-names></name><name><surname>Taylor</surname><given-names>M</given-names></name><name><surname>Jezzard</surname><given-names>P</given-names></name><name><surname>Matthews</surname><given-names>PM</given-names></name><name><surname>Cowen</surname><given-names>PJ</given-names></name></person-group> (<year>2004</year>) <article-title>Increased brain GABA
                        concentrations following acute administration of a selective serotonin
                        reuptake inhibitor</article-title>. <source>Am J Psychiatry</source><volume>161</volume>:
                <fpage>368</fpage>&#x02013;<lpage>370</lpage><pub-id pub-id-type="pmid">14754790</pub-id></mixed-citation></ref><ref id="bibr6-0269881109105679"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bottomley</surname><given-names>PA</given-names></name></person-group> (<year>1987</year>) <article-title>Spatial localization in NMR
                        spectroscopy in vivo</article-title>. <source>Ann N Y Acad Sci</source><volume>508</volume>:
                <fpage>333</fpage>&#x02013;<lpage>348</lpage><pub-id pub-id-type="pmid">3326459</pub-id></mixed-citation></ref><ref id="bibr7-0269881109105679"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brooks</surname><given-names>WM</given-names></name><name><surname>Friedman</surname><given-names>SD</given-names></name><name><surname>Stidley</surname><given-names>CA</given-names></name></person-group> (<year>1999</year>) <article-title>Reproducibility of 1H-MRS in
                        vivo</article-title>. <source>Magn Reson Med</source><volume>41</volume>:
                <fpage>193</fpage>&#x02013;<lpage>197</lpage><pub-id pub-id-type="pmid">10025629</pub-id></mixed-citation></ref><ref id="bibr8-0269881109105679"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Danbolt</surname><given-names>NC</given-names></name></person-group> (<year>2001</year>) <article-title>Glutamate
                    uptake</article-title>. <source>Prog Neurobiol</source><volume>65</volume>: <fpage>1</fpage>&#x02013;<lpage>105</lpage><pub-id pub-id-type="pmid">11369436</pub-id></mixed-citation></ref><ref id="bibr9-0269881109105679"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eastwood</surname><given-names>SL</given-names></name><name><surname>Burnet</surname><given-names>PW</given-names></name><name><surname>Gittins</surname><given-names>R</given-names></name><name><surname>Baker</surname><given-names>K</given-names></name><name><surname>Harrison</surname><given-names>PJ</given-names></name></person-group> (<year>2001</year>) <article-title>Expression of serotonin
                        5-HT(2A) receptors in the human cerebellum and alterations in
                    schizophrenia</article-title>. <source>Synapse</source><volume>42</volume>:
                <fpage>104</fpage>&#x02013;<lpage>114</lpage><pub-id pub-id-type="pmid">11574947</pub-id></mixed-citation></ref><ref id="bibr33-0269881109105679"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>First</surname><given-names>MB</given-names></name><name><surname>Spitzer</surname><given-names>RL</given-names></name><name><surname>Gibbon</surname><given-names>M</given-names></name><name><surname>Williams</surname><given-names>JBW</given-names></name></person-group> (<year>1997</year>) Structured Clinical Interview for DSM-IV
                    Axis I disorders &#x02013; Clinician Version (SCID-CV) American Psychiatric
                    Press, Washington, DC.</mixed-citation></ref><ref id="bibr10-0269881109105679"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harmer</surname><given-names>CJ</given-names></name><name><surname>Mackay</surname><given-names>CE</given-names></name><name><surname>Reid</surname><given-names>CB</given-names></name><name><surname>Cowen</surname><given-names>PJ</given-names></name><name><surname>Goodwin</surname><given-names>GM</given-names></name></person-group> (<year>2006</year>) <article-title>Antidepressant drug treatment
                        modifies the neural processing of nonconscious threat cues</article-title>.
                        <source>Biol Psychiatry</source><volume>59</volume>:
                <fpage>816</fpage>&#x02013;<lpage>820</lpage><pub-id pub-id-type="pmid">16460693</pub-id></mixed-citation></ref><ref id="bibr11-0269881109105679"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harmer</surname><given-names>CJ</given-names></name><name><surname>Shelley</surname><given-names>NC</given-names></name><name><surname>Cowen</surname><given-names>PJ</given-names></name><name><surname>Goodwin</surname><given-names>GM</given-names></name></person-group> (<year>2004</year>) <article-title>Increased positive versus
                        negative affective perception and memory in healthy volunteers following
                        selective serotonin and norepinephrine reuptake inhibition</article-title>.
                        <source>Am J Psychiatry</source><volume>161</volume>:
                <fpage>1256</fpage>&#x02013;<lpage>1263</lpage><pub-id pub-id-type="pmid">15229059</pub-id></mixed-citation></ref><ref id="bibr12-0269881109105679"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hasler</surname><given-names>G</given-names></name><name><surname>Neumeister</surname><given-names>A</given-names></name><name><surname>van der Veen</surname><given-names>JW</given-names></name><name><surname>Tumonis</surname><given-names>T</given-names></name><name><surname>Bain</surname><given-names>EE</given-names></name><name><surname>Shen</surname><given-names>J</given-names></name><etal/></person-group> (<year>2005</year>) <article-title>Normal prefrontal
                        gamma-aminobutyric acid levels in remitted depressed subjects determined by
                        proton magnetic resonance spectroscopy</article-title>. <source>Biol
                        Psychiatry</source><volume>58</volume>:
                <fpage>969</fpage>&#x02013;<lpage>973</lpage><pub-id pub-id-type="pmid">16043137</pub-id></mixed-citation></ref><ref id="bibr13-0269881109105679"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hasler</surname><given-names>G</given-names></name><name><surname>van der Veen</surname><given-names>JW</given-names></name><name><surname>Tumonis</surname><given-names>T</given-names></name><name><surname>Meyers</surname><given-names>N</given-names></name><name><surname>Shen</surname><given-names>J</given-names></name><name><surname>Drevets</surname><given-names>WC</given-names></name></person-group> (<year>2007</year>) <article-title>Reduced prefrontal
                        glutamate/glutamine and gamma-aminobutyric acid levels in major depression
                        determined using proton magnetic resonance spectroscopy</article-title>.
                        <source>Arch Gen Psychiatry</source><volume>64</volume>:
                <fpage>193</fpage>&#x02013;<lpage>200</lpage><pub-id pub-id-type="pmid">17283286</pub-id></mixed-citation></ref><ref id="bibr14-0269881109105679"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hornung</surname><given-names>JP</given-names></name></person-group> (<year>2003</year>) <article-title>The human raphe nuclei and
                        the serotonergic system</article-title>. <source>J Chem Neuroanat</source><volume>26</volume>:
                <fpage>331</fpage>&#x02013;<lpage>343</lpage><pub-id pub-id-type="pmid">14729135</pub-id></mixed-citation></ref><ref id="bibr15-0269881109105679"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hurd</surname><given-names>R</given-names></name><name><surname>Sailasuta</surname><given-names>N</given-names></name><name><surname>Srinivasan</surname><given-names>R</given-names></name><name><surname>Vigneron</surname><given-names>DB</given-names></name><name><surname>Pelletier</surname><given-names>D</given-names></name><name><surname>Nelson</surname><given-names>SJ</given-names></name></person-group> (<year>2004</year>) <article-title>Measurement of brain
                        glutamate using TE-averaged PRESS at 3T</article-title>. <source>Magn Reson
                        Med</source><volume>51</volume>:
                <fpage>435</fpage>&#x02013;<lpage>440</lpage><pub-id pub-id-type="pmid">15004781</pub-id></mixed-citation></ref><ref id="bibr16-0269881109105679"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hyder</surname><given-names>F</given-names></name><name><surname>Patel</surname><given-names>AB</given-names></name><name><surname>Gjedde</surname><given-names>A</given-names></name><name><surname>Rothman</surname><given-names>DL</given-names></name><name><surname>Behar</surname><given-names>KL</given-names></name><name><surname>Shulman</surname><given-names>RG</given-names></name></person-group> (<year>2006</year>) <article-title>Neuronal-glial glucose
                        oxidation and glutamatergic-GABAergic function</article-title>. <source>J
                        Cereb Blood Flow Metab</source><volume>26</volume>:
                <fpage>865</fpage>&#x02013;<lpage>877</lpage><pub-id pub-id-type="pmid">16407855</pub-id></mixed-citation></ref><ref id="bibr17-0269881109105679"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jakab</surname><given-names>RL</given-names></name><name><surname>Goldman-Rakic</surname><given-names>PS</given-names></name></person-group> (<year>1998</year>) <article-title>5-Hydroxytryptamine2A
                        serotonin receptors in the primate cerebral cortex: possible site of action
                        of hallucinogenic and antipsychotic drugs in pyramidal cell apical
                    dendrites</article-title>. <source>Proc Natl Acad Sci U S A</source><volume>95</volume>:
                <fpage>735</fpage>&#x02013;<lpage>740</lpage><pub-id pub-id-type="pmid">9435262</pub-id></mixed-citation></ref><ref id="bibr18-0269881109105679"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jakab</surname><given-names>RL</given-names></name><name><surname>Goldman-Rakic</surname><given-names>PS</given-names></name></person-group> (<year>2000</year>) <article-title>Segregation of serotonin
                        5-HT2A and 5-HT3 receptors in inhibitory circuits of the primate cerebral
                        cortex</article-title>. <source>J Comp Neurol</source><volume>417</volume>:
                <fpage>337</fpage>&#x02013;<lpage>348</lpage><pub-id pub-id-type="pmid">10683608</pub-id></mixed-citation></ref><ref id="bibr19-0269881109105679"><mixed-citation publication-type="book"><person-group person-group-type="editor"><name><surname>Lentner</surname><given-names>C</given-names></name></person-group> (ed) (<year>1981</year>) <source>Geigy Scientific Tables.</source><publisher-loc>Basel</publisher-loc>:
                    <publisher-name>Ciba-Geigy</publisher-name></mixed-citation></ref><ref id="bibr20-0269881109105679"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malhi</surname><given-names>GS</given-names></name><name><surname>Valenzuela</surname><given-names>M</given-names></name><name><surname>Wen</surname><given-names>W</given-names></name><name><surname>Sachdev</surname><given-names>P</given-names></name></person-group> (<year>2002</year>) <article-title>Magnetic resonance
                        spectroscopy and its applications in psychiatry</article-title>.
                        <source>Aust N Z J Psychiatry</source><volume>36</volume>: <fpage>31</fpage>&#x02013;<lpage>43</lpage><pub-id pub-id-type="pmid">11929436</pub-id></mixed-citation></ref><ref id="bibr21-0269881109105679"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mescher</surname><given-names>M</given-names></name><name><surname>Merkle</surname><given-names>H</given-names></name><name><surname>Kirsch</surname><given-names>J</given-names></name><name><surname>Garwood</surname><given-names>M</given-names></name><name><surname>Gruetter</surname><given-names>R</given-names></name></person-group> (<year>1998</year>) <article-title>Simultaneous in vivo spectral
                        editing and water suppression</article-title>. <source>NMR Biomed</source><volume>11</volume>:
                <fpage>266</fpage>&#x02013;<lpage>272</lpage><pub-id pub-id-type="pmid">9802468</pub-id></mixed-citation></ref><ref id="bibr22-0269881109105679"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Michael</surname><given-names>N</given-names></name><name><surname>Erfurth</surname><given-names>A</given-names></name><name><surname>Ohrmann</surname><given-names>P</given-names></name><name><surname>Arolt</surname><given-names>V</given-names></name><name><surname>Heindel</surname><given-names>W</given-names></name><name><surname>Pfleiderer</surname><given-names>B</given-names></name></person-group> (<year>2003</year>) <article-title>Metabolic changes within the
                        left dorsolateral prefrontal cortex occurring with electroconvulsive therapy
                        in patients with treatment resistant unipolar depression</article-title>.
                        <source>Psychol Med</source><volume>33</volume>:
                <fpage>1277</fpage>&#x02013;<lpage>1284</lpage><pub-id pub-id-type="pmid">14580081</pub-id></mixed-citation></ref><ref id="bibr23-0269881109105679"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pfleiderer</surname><given-names>B</given-names></name><name><surname>Michael</surname><given-names>N</given-names></name><name><surname>Erfurth</surname><given-names>A</given-names></name><name><surname>Ohrmann</surname><given-names>P</given-names></name><name><surname>Hohmann</surname><given-names>U</given-names></name><name><surname>Wolgast</surname><given-names>M</given-names></name><etal/></person-group> (<year>2003</year>) <article-title>Effective electroconvulsive
                        therapy reverses glutamate/glutamine deficit in the left anterior cingulum
                        of unipolar depressed patients</article-title>. <source>Psychiatry Res</source><volume>122</volume>:
                <fpage>185</fpage>&#x02013;<lpage>192</lpage><pub-id pub-id-type="pmid">12694892</pub-id></mixed-citation></ref><ref id="bibr24-0269881109105679"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Provencher</surname><given-names>SW</given-names></name></person-group> (<year>1993</year>) <article-title>Estimation of metabolite
                        concentrations from localized in vivo proton NMR spectra</article-title>.
                        <source>Magn Reson Med</source><volume>30</volume>:
                <fpage>672</fpage>&#x02013;<lpage>679</lpage><pub-id pub-id-type="pmid">8139448</pub-id></mixed-citation></ref><ref id="bibr25-0269881109105679"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sanacora</surname><given-names>G</given-names></name><name><surname>Gueorguieva</surname><given-names>R</given-names></name><name><surname>Epperson</surname><given-names>CN</given-names></name><name><surname>Wu</surname><given-names>YT</given-names></name><name><surname>Appel</surname><given-names>M</given-names></name><name><surname>Rothman</surname><given-names>DL</given-names></name><etal/></person-group> (<year>2004</year>) <article-title>Subtype-specific alterations
                        of gamma-aminobutyric acid and glutamate in patients with major
                    depression</article-title>. <source>Arch Gen Psychiatry</source><volume>61</volume>:
                <fpage>705</fpage>&#x02013;<lpage>713</lpage><pub-id pub-id-type="pmid">15237082</pub-id></mixed-citation></ref><ref id="bibr26-0269881109105679"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sanacora</surname><given-names>G</given-names></name><name><surname>Zarate</surname><given-names>CA</given-names></name><name><surname>Krystal</surname><given-names>JH</given-names></name><name><surname>Manji</surname><given-names>HK</given-names></name></person-group> (<year>2008</year>) <article-title>Targeting the glutamatergic
                        system to develop novel, improved therapeutics for mood
                    disorders</article-title>. <source>Nat Rev Drug Discov</source><volume>7</volume>:
                <fpage>426</fpage>&#x02013;<lpage>437</lpage><pub-id pub-id-type="pmid">18425072</pub-id></mixed-citation></ref><ref id="bibr27-0269881109105679"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>J</given-names></name><name><surname>Petersen</surname><given-names>KF</given-names></name><name><surname>Behar</surname><given-names>KL</given-names></name><name><surname>Brown</surname><given-names>P</given-names></name><name><surname>Nixon</surname><given-names>TW</given-names></name><name><surname>Mason</surname><given-names>GF</given-names></name><etal/></person-group> (<year>1999</year>) <article-title>Determination of the rate of
                        the glutamate/glutamine cycle in the human brain by in vivo 13C
                    NMR</article-title>. <source>Proc Natl Acad Sci U S A</source><volume>96</volume>:
                <fpage>8235</fpage>&#x02013;<lpage>8240</lpage><pub-id pub-id-type="pmid">10393978</pub-id></mixed-citation></ref><ref id="bibr28-0269881109105679"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taylor</surname><given-names>M</given-names></name><name><surname>Murphy</surname><given-names>SE</given-names></name><name><surname>Selvaraj</surname><given-names>S</given-names></name><name><surname>Wylezinkska</surname><given-names>M</given-names></name><name><surname>Jezzard</surname><given-names>P</given-names></name><name><surname>Cowen</surname><given-names>PJ</given-names></name><etal/></person-group> (<year>2008</year>) <article-title>Differential effects of
                        citalopram and reboxetine on cortical Glx measured with proton MR
                        spectroscopy</article-title>. <source>J Psychopharmacol</source><volume>22</volume>:
                <fpage>473</fpage>&#x02013;<lpage>476</lpage><pub-id pub-id-type="pmid">18208909</pub-id></mixed-citation></ref><ref id="bibr29-0269881109105679"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taylor</surname><given-names>MJ</given-names></name><name><surname>Freemantle</surname><given-names>N</given-names></name><name><surname>Geddes</surname><given-names>JR</given-names></name><name><surname>Bhagwagar</surname><given-names>Z</given-names></name></person-group> (<year>2006</year>) <article-title>Early onset of selective
                        serotonin reuptake inhibitor antidepressant action: systematic review and
                        meta-analysis</article-title>. <source>Arch Gen Psychiatry</source><volume>63</volume>:
                <fpage>1217</fpage>&#x02013;<lpage>1223</lpage><pub-id pub-id-type="pmid">17088502</pub-id></mixed-citation></ref><ref id="bibr30-0269881109105679"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vanhamme</surname><given-names>L</given-names></name><name><surname>van den Boogaart</surname><given-names>A</given-names></name><name><surname>Van Huffel</surname><given-names>S</given-names></name></person-group> (<year>1997</year>) <article-title>Improved method for accurate
                        and efficient quantification of MRS data with use of prior
                    knowledge</article-title>. <source>J Magn Reson</source><volume>129</volume>:
                <fpage>35</fpage>&#x02013;<lpage>43</lpage><pub-id pub-id-type="pmid">9405214</pub-id></mixed-citation></ref><ref id="bibr31-0269881109105679"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yildiz-Yesiloglu</surname><given-names>A</given-names></name><name><surname>Ankerst</surname><given-names>DP</given-names></name></person-group> (<year>2006</year>) <article-title>Review of 1H magnetic
                        resonance spectroscopy findings in major depressive disorder: a
                        meta-analysis</article-title>. <source>Psychiatry Res</source><volume>147</volume>: <fpage>1</fpage>&#x02013;<lpage>25</lpage><pub-id pub-id-type="pmid">16806850</pub-id></mixed-citation></ref><ref id="bibr32-0269881109105679"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Brady</surname><given-names>M</given-names></name><name><surname>Smith</surname><given-names>S</given-names></name></person-group> (<year>2001</year>) <article-title>Segmentation of brain MR
                        images through a hidden Markov random field model and the
                        expectation-maximization algorithm</article-title>. <source>IEEE Trans Med
                        Imaging</source><volume>20</volume>: <fpage>45</fpage>&#x02013;<lpage>57</lpage><pub-id pub-id-type="pmid">11293691</pub-id></mixed-citation></ref></ref-list></back></article>